Literature DB >> 20048028

Myelodysplastic syndromes: a practical approach to diagnosis and treatment.

Afsaneh Barzi1, Mikkael A Sekeres.   

Abstract

The myelodysplastic syndromes (MDS) are clonal bone marrow disorders that lead to underproduction of normal blood cells. The consequent cytopenias result in infections and bleeding complications. MDS transform to acute myeloid leukemia in one-third of patients. The number of diagnoses has exploded in the past decade as a result of increased recognition and understanding of the disease and the aging of the population. New therapies can extend life. MDS are now considered the most common form of leukemia, and in some cases deserve immediate intervention. This review describes common presentations of MDS, optimal diagnostic approaches, and therapies for lower-and higher-risk disease.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20048028     DOI: 10.3949/ccjm.77a.09069

Source DB:  PubMed          Journal:  Cleve Clin J Med        ISSN: 0891-1150            Impact factor:   2.321


  11 in total

1.  Monocyte function in patients with myelodysplastic syndrome.

Authors:  Daniel A Pollyea; Brenna R Hedin; Brian P O'Connor; Scott Alper
Journal:  J Leukoc Biol       Date:  2018-04-14       Impact factor: 4.962

Review 2.  A primary care approach to myelodysplastic syndromes.

Authors:  Djamshed Samiev; Vijaya R Bhatt; Joel D Armitage; Lori J Maness; Mojtaba Akhtari
Journal:  Korean J Fam Med       Date:  2014-05-22

Review 3.  Revisiting the case for genetically engineered mouse models in human myelodysplastic syndrome research.

Authors:  Ting Zhou; Marsha C Kinney; Linda M Scott; Sandra S Zinkel; Vivienne I Rebel
Journal:  Blood       Date:  2015-06-15       Impact factor: 22.113

Review 4.  Treatment-related myelodysplasia in patients with primary brain tumors.

Authors:  Joachim M Baehring; Peter W Marks
Journal:  Neuro Oncol       Date:  2012-03-29       Impact factor: 12.300

5.  Optimizing outcomes with azacitidine: recommendations from Canadian centres of excellence.

Authors:  R A Wells; B Leber; N Y Zhu; J M Storring
Journal:  Curr Oncol       Date:  2014-02       Impact factor: 3.677

Review 6.  Biology of the bone marrow microenvironment and myelodysplastic syndromes.

Authors:  Erinn B Rankin; Anupama Narla; Joseph K Park; Shuo Lin; Kathleen M Sakamoto
Journal:  Mol Genet Metab       Date:  2015-07-20       Impact factor: 4.797

7.  Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia.

Authors:  Christopher N Hahn; Chan-Eng Chong; Catherine L Carmichael; Ella J Wilkins; Peter J Brautigan; Xiao-Chun Li; Milena Babic; Ming Lin; Amandine Carmagnac; Young K Lee; Chung H Kok; Lucia Gagliardi; Kathryn L Friend; Paul G Ekert; Carolyn M Butcher; Anna L Brown; Ian D Lewis; L Bik To; Andrew E Timms; Jan Storek; Sarah Moore; Meryl Altree; Robert Escher; Peter G Bardy; Graeme K Suthers; Richard J D'Andrea; Marshall S Horwitz; Hamish S Scott
Journal:  Nat Genet       Date:  2011-09-04       Impact factor: 38.330

8.  The role of magnetic resonance imaging in the evaluation of transfusional iron overload in myelodysplastic syndromes.

Authors:  Emmanouil Petrou; Sophie Mavrogeni; Vasiliki Karali; Genovefa Kolovou; Marie-Christine Kyrtsonis; Petros P Sfikakis; Panayiotis Panayiotidis
Journal:  Rev Bras Hematol Hemoter       Date:  2015-05-19

9.  Cytogenetic features in primary myelodysplastic syndrome Egyptian patients.

Authors:  Yasser Elnahass; Lamiaa Youssif
Journal:  J Adv Res       Date:  2018-02-07       Impact factor: 10.479

10.  Response Assessment to Erythropoietin-Zeta (Epo-Alpha Biosimilar) Therapy in Low-Risk Myelodysplastic Syndromes.

Authors:  Calogero Vetro; Valeria Di Giacomo; Donato Mannina; Silvana Magrin; Antonio Mulè; Maria Enza Mitra; Sergio Siragusa; Andrea Duminuco; Bruno Garibaldi; Maria Cristina Emanuela Vadalà; Francesco Di Raimondo; Giuseppe A Palumbo
Journal:  J Clin Med       Date:  2022-03-17       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.